Hemolytic Disease Of The Newborn With Kell Alloimmunization C0472751
A condition where a pregnant woman's antibodies attack her baby's red blood cells. It affects unborn and newborn babies when the mother has Kell antibodies. Treatment may include transfusions and careful monitoring during pregnancy.
Key facts at a glance
- ICD-10
- D64.9
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Hydrops fetalis
Severe hemolytic disease requiring exchange transfusion
Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Varies
Neonatal jaundice
(hematologic)Fetal anemia
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Intrauterine Transfusion
Direct transfusion of packed red blood cells into the fetal circulation to treat severe anemia caused by maternal anti-Kell antibodies. Performed under ultrasound guidance by a specialized maternal-fetal medicine team.
Phototherapy
Exposure of the newborn to specific blue-spectrum light wavelengths that convert bilirubin into water-soluble forms for excretion. Standard treatment for neonatal hyperbilirubinemia resulting from hemolysis.
Additional treatment options
Exchange Transfusion
Replacement of the newborn's blood volume with donor blood to rapidly reduce circulating bilirubin and maternal antibodies. Reserved for severe hyperbilirubinemia unresponsive to phototherapy.
procedureSerial MCA-PSV Doppler Ultrasound
Non-invasive ultrasound measurement of fetal middle cerebral artery peak systolic velocity to detect and monitor fetal anemia severity and guide transfusion timing.
monitoringHigh-Dose IVIG
Intravenous immunoglobulin administration to the pregnant person may reduce maternal antibody-mediated fetal red blood cell destruction. Often used as adjunct therapy.
medicationWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Hemolytic Disease Of The Newborn With Kell Alloimmunization C0472751?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Hemolytic Disease Of The Newborn With Kell Alloimmunization C0472751. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy